TY - JOUR
T1 - Development of autotaxin inhibitors
T2 - an overview of the patent and primary literature
AU - Castagna, Diana
AU - Budd, David C.
AU - MacDonald, Simon J. F.
AU - Jamieson, Craig
AU - Watson, Allan J. B.
PY - 2016/6/23
Y1 - 2016/6/23
N2 - The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a result, ATX-LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
AB - The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a result, ATX-LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
KW - autotaxin-lysophophatidic acid
KW - ATX-LPA
KW - disease
KW - ATX inhibitors
UR - https://www.scopus.com/pages/publications/84976320613
UR - http://pubs.acs.org/journal/jmcmar
U2 - 10.1021/acs.jmedchem.5b01599
DO - 10.1021/acs.jmedchem.5b01599
M3 - Article
AN - SCOPUS:84976320613
SN - 0022-2623
VL - 59
SP - 5604
EP - 5621
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 12
ER -
